Cells detect and respond to environmental changes using intracellular networks, and defects in the wiring of these networks contribute to diseases. For example, Toll-like receptors (TLRs) sense microbial molecules and trigger pathways critical for host defense. Genetic defects in components of the TLR and other pathogen-sensing pathways have been linked to human diseases. Hence, rational targeting of these pathways should help to manipulate immune responses associated with infections, autoimmunity, or vaccines. A fundamental challenge is to dissect the intracellular networks mobilized by pathogen-sensing pathways. Here we present approaches to dissect the TLR network of innate immune dendritic cells (DCs), focusing on two regulatory layers: signaling and transcription. First, we present a strategy to systematically perturb candidate regulators and monitor cellular transcriptional responses. We apply this approach to derive regulatory networks that control the transcriptional response to TLR engagement by microbial molecules. Our approach revealed the regulatory functions of 125 transcription factors (TFs), chromatin modifiers, and RNA binding proteins, which enabled the construction of a network model consisting of 24 core regulators and 76 “fine-tuners” that help explain how TLR pathways achieve specificity. Second, we report the systematic discovery of signaling components in TLR responses. By combining transcriptional profiling, genetic and small molecule perturbations, and phosphoproteomics, we uncover 35 signaling regulators, including 16 known members of the TLR signaling pathways. In particular, we find that Polo-like kinases (Plk) 2 and 4 are essential components of antiviral pathways in vitro and in vivo and activate a signaling branch involving a dozen proteins, among which is Tnfaip2, a gene associated with autoimmune diseases but whose role was unknown. Lastly, we expand these approaches to integrate functional and physical interactions linking the ‘signaling-to-transcription’ TLR network. By combining our perturbation-based approach with measurements of physical interactions, including phosphorylation, protein complexes, and TF binding to DNA, we uncover 30 signaling regulators mechanistically linked to 19 downstream TFs. The integration of these datasets into a model reveals the organization of the TLR response. Overall, these studies illustrate the power of combining systematic measurements and perturbations to elucidate complex intracellular circuits and discover potential therapeutic targets.

Over the past several decades, our understanding of the immune system has advanced considerably. With it, an appreciation for its role in a number of diseases, such as cancer and infection has significantly grown. While our increased understanding of the immunological mechanisms underlying these diseases has improved treatment, considerable morbidity and mortality from these illnesses still exists signifying the need for more effective and innovative therapies. Dendritic cell (DC) therapy has been shown to be a promising approach to induce strong immune responses for immunotherapy, and biomaterial-based strategies have been developed to target DCs in vivo to facilitate this purpose. Given the importance of calcium in DC function and activation, we hypothesized that we could develop a biomaterial-based approach to locally and specifically control calcium signaling in DCs in vivo as a novel strategy for immunotherapy. Our first sub-hypothesis was that the calcium used to crosslink alginate gels, a commonly used biomaterial, could activate DCs in vitro; our second sub-hypothesis was that calcium ionophore A23187 could be delivered from biomaterials to activate DCs in vitro; and our third sub-hypothesis was that calcium used to crosslink alginate gels and/or controlled delivery of A23187 could increase local inflammation in vivo. We found that both the calcium released from calcium alginate gels and A23187 matured DCs and enhanced TLR-induced inflammatory cytokine secretion in vitro. Although we were unable to effectively deliver A23187 in vivo, calcium alginate gels injected subcutaneously were able to upregulate a number of inflammatory cytokines and chemokines relative to barium alginate gels. Likewise, when LPS was delivered from calcium alginate gels, the inflammatory effects of LPS on surrounding tissue were enhanced compared to when it was delivered from barium alginate gels. Thus, we confirmed that the calcium crosslinker in alginate gels could activate DCs, and provided a proof-of-principle that calcium signaling could be harnessed in vivo to enhance the immune response. Not only does this work impact the future of biomaterial design, but it may also enhance our understanding of DC biology. This thesis lays the groundwork for a novel and potentially effective strategy for enhancing DC activation in vivo, and suggests that ion signaling pathways in other cell types (both immune and non-immune) could also be targeted using biomaterials. / Engineering and Applied Sciences

Topical antigen (Ag) application mimics natural Ag exposure across the skin. Soluble Ag introduced through this route requires cross-presentation by dendritic cells (DCs) to generate CD8 T cell responses, including skin-homing T cells. DCs process Ag for display to other immune cells, and stimulate T cells to release cytokines or directly lyse infected cells. Some T cells are further stimulated to express homing markers allowing them to enter non-lymphoid tissue such as the skin or the gut.

The field of immunology has advanced tremendously over the last 40 years, with seminal findings that have guided the development of powerful new therapies. However, the ability to induce safe and long-lasting antigen-specific tolerance has remained elusive. A therapy that could prevent the immune system from aberrantly destroying self-tissues, without impairing its capacity to eliminate dangerous pathogens, would be transformative for the treatment of autoimmune diseases. In addition, such a therapy could also greatly advance the field of organ transplantation by inducing antigen-specific tolerance to prevent graft rejection. / Engineering and Applied Sciences

published_or_final_version / Medical Sciences / Master / Master of Medical Sciences

Immunotherapy has been proposed as an alternative to conventional cancer therapies due to its reduced toxicity and ability to induce long-lasting anti-tumor immune responses. Dendritic cell (DC) vaccination is one immune-based anti-cancer strategy that has received attention due to the ability of DC to process and present antigen to T lymphocytes to initiate immune responses. However, the clinical efficacy of DC-based immunotherapy against established cancers in humans has been extremely low and despite recent advances, objective response rates in DC vaccine trials are rarely above 10%. This lack of efficacy is due in part to immunosuppressive factors, such as transforming growth factor &beta (TGF-&beta), present in the tumor microenvironment that promote tumor immune escape. Therefore, TGF-&beta represents a major barrier to effective cancer immunotherapy and strategies to neutralize this cytokine may lead to more efficacious DC vaccines.In this study, we employed two small molecule transforming growth factor &beta receptor type I (T&betaRI/ALK5) kinase inhibitors (HTS466284 and SM16) in combination with DC vaccines to treat established TGF-&beta-secreting 4T1 mammary tumors. The results demonstrate that while both inhibitors blocked the effects of TGF-&beta in vitro, HTS466284 by itself or in combination with DC vaccination was unable to consistently control the growth and metastasis of established 4T1 tumors. In contrast, SM16 inhibited the growth of established tumors when delivered orally and suppressed the formation of pulmonary metastases when delivered orally or via daily intraperitoneal (i.p.) injection. The efficacy of SM16 was dependent on cellular immunity as this drug had no effect in immunodeficient SCID mice. Furthermore, orally delivered SM16 in combination with DC vaccination led to complete tumor regression in several mice that correlated with increased T cell infiltration of the primary tumor and enhanced in vitro IFN-gamma production and tumor-specific cytolytic activity by splenocytes. Finally, a suboptimal dose of SM16 that failed to control primary tumor growth on its own synergized with DC vaccination to inhibit the growth of established 4T1 tumors. These findings suggest that blockade of TGF-&beta signaling using a small molecule T&betaRI/ALK5 kinase antagonist may be an effective strategy to bolster the efficacy of DC-based cancer vaccines.

No description available.

Tuberculosis, caused by Mycobacterium tuberculosis infection, results in the development of granulomas in affected tissues. These structures are formed by a myeloid cell core including multinucleated giant cells and surrounded by T lymphocytes. We studied mechanisms of survival, formation and functions of giant cells in Mycobacterium granulomas. Previously, our group showed that the cytokine IL-17A induces the fusion of dendritic cells (DC). Here, we identified molecules induced by the IL-17A genetic program in myeloid cells: BFL1 regulated DC survival, while the chemokines CCL2 and CCL20 directed clustering required for DC fusion. In situ, in human TB granulomas, we found that IL-17A was expressed by T lymphocytes while BFL1, CCL2 and CCL20 were expressed by the mono- and multi-nucleated myeloid cells. Then we characterized phenotype, immune functions and microbicidal activity of IL-17A-treated DC and their derived giant cells. They expressed a mixed DC-macrophage phenotype, retained classical DC functions, synthesized several destructive enzymes and had increased and differential microbicidal activities against Mycobacterium species. We named GMIC (giant myeloid inflammatory cells) these IL-17A-dependent giant cells, and propose that they constitute a new inflammatory myeloid effector with potent microbicidal activities. Altogether, our results show that IL-17A may participate in the maintenance of the myeloid core of human tuberculosis granuloma by promoting the formation of GMIC with potent destructive and microbicidal functions. The molecular mechanisms we have documented should help the development of new tuberculosis therapeutic and vaccination strategies.

Lactic acid bacteria (LAB) are of interest because of their potential to modulate immune responses. The effects of LAB range from regulation to stimulation of the immune system. It has been reported that LAB affect health via two main mechanisms: directly through physical interactions between LAB and cells of the immune system, and indirectly through the products of these bacteria. The studies presented in this thesis examine the direct and indirect effects of LAB on the immune system specifically on murine dendritic cells (DCs). Mouse DCs (in form of the DC2.4 cell line) were treated in vitro with a fraction of bovine milk fermented with Lactobacillus helveticus-2 (LH-2) or three synthetic peptides identified within the fermented milk fraction. Cell culture supernatants were analyzed for presence of tumor necrosis factor (TNF)-α and interleukin (IL)-6 to determine the effects of LAB on DC activation. The results of this study showed that the ability of the milk derived fraction and the synthetic peptides to induce DC activation and production of pro-inflammatory cytokines was limited, suggesting that these peptides may induce regulatory immune responses. A series of studies was performed in vitro to investigate the effects of six LAB species and strains, (LH-2), Lactobacillus acidophilus-5 (La-5), Lactobacillus acidophilus-115 (La-115), Lactobacillus acidophilus-116 (La-116), Lactobacillus acidophilus-14 (La-14), and Lactobacillus salivarius, on maturation and activation of DC2.4. Production of TNF-α, IL-6 and IL-10 by DCs was determined after treating cells with live LAB. The expression of DC maturation markers, CD80 and CD40, was also measured using flow cytometry after stimulation with LAB. In addition, the expression of toll-like receptors (TLRs) 2, 4 and 9 by DCs stimulated with LAB was measured. Our results revealed that LAB act differentially on pro-inflammatory and anti-inflammatory cytokine production and induction of co-stimulatory molecules by DCs. Specifically, L. salivarius was found to be the most effective LAB to induce pro-inflammatory cytokine production and expression of co-stimulatory molecules. Moreover, La-14, La-116 and La-5 induced moderate maturation and activation of DCs. On the other hand, LH-2 and La-115 are the least likely lactobacilli to induce DC response. In conclusion, various strains and species of LAB can differentially regulate DC activation and maturation, raising the possibility that these microbes can influence and steer immune responses of the host.

No description available.